Wikipedia
Elafibranor
Elafibranor (GFT505) a experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).
Elafibranor is a dual PPARα/δ agonist.
Elafibranor is mainly focused on the treatment of NASH disease.